Literature DB >> 19440928

HCV treatment decision-making substance use experiences and hepatitis C treatment decision-making among HIV/HCV Coinfected Adults.

Lisa M Fink Ogawa1, Carol Bova.   

Abstract

Hepatitis C virus (HCV) infection is a major source of morbidity and mortality among substance users and persons living with human immunodeficiency virus (HIV) infection. Treatment for chronic HCV infection involves complex decision-making. These decisions are even more complicated in persons with HIV and substance use related problems. A secondary analyses of qualitative data collected in the United States (2004-2005) with 31 HIV/HCV coinfected adults (48% women; mean age 44.7 years) revealed three themes related to substance use (substance use evolution, revolving door: going back out and reconstructing life) and two HCV treatment decision-making themes (HCV infection treatment issues: not a priority, fear, misinformation and get clean and try it). Study limitations and implications are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19440928     DOI: 10.1080/10826080802486897

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  8 in total

1.  Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Glenn Wagner; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Mallory Witt; Laveeza Bhatti; Matthew Bidwell Goetz
Journal:  AIDS Patient Care STDS       Date:  2011-08-08       Impact factor: 5.078

2.  Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Gery Ryan; Laveeza Bhatti; Matthew Goetz; Mallory Witt; Glenn Wagner
Journal:  AIDS Patient Care STDS       Date:  2009-12       Impact factor: 5.078

3.  Hepatitis C treatment experiences and decision making among patients living with HIV infection.

Authors:  Carol Bova; Lisa Fink Ogawa; Susan Sullivan-Bolyai
Journal:  J Assoc Nurses AIDS Care       Date:  2009-10-22       Impact factor: 1.354

Review 4.  Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.

Authors:  Christine U Oramasionwu; Heather N Moore; Joshua C Toliver
Journal:  AIDS Patient Care STDS       Date:  2014-04-16       Impact factor: 5.078

5.  Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Authors:  Glenn Wagner; Karen Chan Osilla; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Laveeza Bhatti; Mallory Witt; Matthew Bidwell Goetz
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2012-05-07

6.  Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.

Authors:  Peter Varunok; Eric Lawitz; Kimberly L Beavers; Gary Matusow; Ruby Leong; Nathalie Lambert; Coen Bernaards; Jonathan Solsky; Barbara J Brennan; Cynthia Wat; Anne Bertasso
Journal:  Patient Prefer Adherence       Date:  2011-11-24       Impact factor: 2.711

7.  Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment.

Authors:  Jessica L Zuchowski; Alison B Hamilton; Jeffrey M Pyne; Jack A Clark; Aanand D Naik; Donna L Smith; Fasiha Kanwal
Journal:  BMC Gastroenterol       Date:  2015-10-01       Impact factor: 3.067

Review 8.  The ongoing impacts of hepatitis c--a systematic narrative review of the literature.

Authors:  Emma R Miller; Stephen McNally; Jack Wallace; Marisa Schlichthorst
Journal:  BMC Public Health       Date:  2012-08-18       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.